CHF92.73
1.01% yesterday
SIX Swiss Exchange, May 28, 05:30 pm CET
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Novartis Stock price

CHF92.73
-0.67 0.72% 1M
-0.65 0.70% 6M
+4.03 4.54% YTD
+1.62 1.78% 1Y
+10.99 13.45% 3Y
+14.70 18.84% 5Y
+11.29 13.86% 10Y
SIX Swiss Exchange, Closing price Wed, May 28 2025
-0.95 1.01%
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Key metrics

Market capitalization CHF178.54b
Enterprise Value CHF198.43b
P/E (TTM) P/E ratio 17.45
EV/FCF (TTM) EV/FCF 16.16
EV/Sales (TTM) EV/Sales 4.50
P/S ratio (TTM) P/S ratio 4.05
P/B ratio (TTM) P/B ratio 5.78
Dividend yield 3.74%
Last dividend (FY24) CHF3.50
Revenue growth (TTM) Revenue growth 11.57%
Revenue (TTM) Revenue CHF44.06b
EBIT (operating result TTM) EBIT CHF14.42b
Free Cash Flow (TTM) Free Cash Flow CHF12.28b
Cash position CHF5.90b
EPS (TTM) EPS CHF5.37
P/E forward 16.59
P/S forward 3.94
EV/Sales forward 4.38
Show more

Create a Free Account to create an Novartis alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Novartis Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Novartis forecast:

5x Buy
19%
15x Hold
58%
6x Sell
23%

Analyst Opinions

26 Analysts have issued a Novartis forecast:

Buy
19%
Hold
58%
Sell
23%

Financial data from Novartis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
44,055 44,055
12% 12%
100%
- Direct Costs 10,711 10,711
3% 3%
24%
33,344 33,344
15% 15%
76%
- Selling and Administrative Expenses 10,573 10,573
3% 3%
24%
- Research and Development Expense 7,777 7,777
12% 12%
18%
14,619 14,619
55% 55%
33%
- Depreciation and Amortization 201 201
212% 212%
0%
EBIT (Operating Income) EBIT 14,418 14,418
54% 54%
33%
Net Profit 10,637 10,637
16% 16%
24%

In millions CHF.

Don't miss a Thing! We will send you all news about Novartis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis Stock News

marktEINBLICKE
13 days ago
Der Schweizer Pharmakonzern hatte trotz des US-Gegenwinds zuletzt häufiger gute Nachrichten parat - zur Freude der Aktionäre.
AD HOC NEWS
29 days ago
Novartis CH0012005267 stärkt seine Pipeline im Bereich Nierenerkrankungen mit der Übernahme von Regulus Therapeutics.
AD HOC NEWS
about one month ago
Das Analysehaus Jefferies hat die Einstufung für Novartis CH0012005267 auf "Hold" mit einem Kursziel von 100 Franken belassen.
More Novartis News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 76,057
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today